Registered number: 06732272

CARECAPITAL (SOUTHAMPTON) LIMITED UNAUDITED DIRECTOR'S REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022



Company Information

Director

M J Sinclair

Company secretary

G S Pughe and H E A Clarke

Registered number

06732272

Registered office

143 Harley Street Ground Floor London W1G 6BH

Contents

| | Page |
|---|-------|
| Director's report | 1 |
| Statement of comprehensive income (incorporating the profit and loss account) | 2 |
| Balance sheet | 3 |
| Statement of changes in equity | 4 |
| Notes to the financial statements | 5 - 7 |

Director's report For the Year Ended 31 December 2022

The director presents his report and the financial statements for the year ended 31 December 2022.

Principal activity

The company was dormant throughout the year.

Director

The director who served during the year was:

M J Sinclair

Liability insurance

The company has procured liability insurance for the director and officers of the company. There are no outstanding claims or provisions at the balance sheet date.

Small companies note

In preparing this report, the director has taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board on

26 September 2023

and signed on its behalf.

G S Pughe Secretary

Statement of comprehensive income For the Year Ended 31 December 2022

The Company has not traded during the year or the preceding financial year. During these periods, the Company received no income and incurred no expenditure and therefore made neither profit or loss.

CARECAPITAL (SOUTHAMPTON) LIMITED Registered number: 06732272

| Balance shee As at 31 December | = = | |
|---------------------------------------|-----------|-----------|
| | 2022 £ | 2021 £ |
| Total assets less current liabilities | - | - |
| Net assets | | - |
| Capital and reserves | | |
| Called up share capital | 1,000 | 1,000 |
| Profit and loss account | (1,000) | (1,000) |
| | - | |

For the year ended 31 December 2022 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on

26 SEPTEMBER 2023

M J Sinclair Director

The notes on pages 5 to 7 form part of these financial statements.

Statement of changes in equity For the Year Ended 31 December 2022

| | Called up share capital £ | Profit and loss account £ | Total equity |
|---------------------|---------------------------------|---------------------------|--------------|
| At 1 January 2022 | 1,000 | (1,000) | - |
| At 31 December 2022 | 1,000 | (1,000) | - |

The notes on pages 5 to 7 form part of these financial statements.

Statement of changes in equity For the Year Ended 31 December 2021

| • | Called up share capital | Profit and loss account | Total equity |
|---------------------|----------------------------|-------------------------|--------------|
| | £ | £ | £ |
| At 1 January 2021 | 1,000 | (1,000) | - |
| At 31 December 2021 | 1,000 | (1,000) | - |
| | | | |

The notes on pages 5 to 7 form part of these financial statements.

Notes to the financial statements For the Year Ended 31 December 2022

1. General information

Carecapital (Southampton) Limited is a limited liability company incorporated in England. The registered office is 143 Harley Street, Ground Floor, London, England, W1G 6BH.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The figures have been rounded to the nearest pound.

The accounts have been prepared on a going concern basis. The company does not expect to incur any significant expenses in the future however the company is dependent on its ultimate parent company Advanced Oncotherapy plc to settle any expenses incurred. The directors of Advanced Oncotherapy plc consider that there are still sufficient funds available to support the company and have confirmed that Advanced Oncotherapy will continue to provide financial support to the company for at least the next 12 months as and when required.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3).

The following principal accounting policies have been applied:

2.2 Financial Reporting Standard 102 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 7 Statement of Cash Flows;
- the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
- the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
- the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A,
- the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of Advanced Oncotherapy plc as at 31 December 2022 and these financial statements may be obtained from 143 Harley Street, Ground Floor, London, England, W1G 6BH.

Notes to the financial statements For the Year Ended 31 December 2022

2. Accounting policies (continued)

2.3 Deferred taxation

Full provision is made for deferred tax assets and liabilities arising from all timing differences between the recognition of gains and losses in the financial statements and recognition in the tax computation.

A net deferred tax asset is recognised only if it can be regarded as more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

Deferred tax assets and liabilities are calculated at the tax rates expected to be effective at the time the timing differences can be deducted.

Deferred tax assets and liabilities are not discounted.

3. Judgements in applying accounting policies and key sources of estimation uncertainty

Judgements

There are no judgements that are considered to have a significant effect on the amounts recognised in the financial statements.

Estimates

There are no key assumptions concerning the future or other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

4. Employees

The average monthly number of employees, including directors, during the year was 1 (2021 - 1).

5. Potential deferred tax

| | 2022 £ | 2021 £ |
|----------------------------|-----------|-----------|
| Tax losses carried forward | 104,287 | 104,287 |
| | 104,287 | 104,287 |

A deferred tax asset has not been recognised on the grounds of future uncertainty regarding the timing of the recovery of the tax losses.

Notes to the financial statements For the Year Ended 31 December 2022

6. Share capital

| | 2022 £ | 2021 £ |
|--|-----------|-----------|
| Allotted, called up and fully paid | | |
| 1,000 (2021 - 1,000) Ordinary shares of £1.00 each | 1,000 | 1,000 |

Ordinary shares carry full voting rights and rights to a dividend.

7. Reserves

Profit & loss account

The profit and loss account reserve represents all current and prior periods retained profits and losses.

8. Ultimate controlling party and related party transactions

The company's immediate parent company is Carecapital Limited, a company registered in England. The ultimate parent company is Advanced Oncotherapy plc, a company incorporated in Great Britain and registered in England.

The company has taken advantage of the exemptions available under paragraph 33.1A of Financial Reporting Standard 102, not to disclose any transactions or balances with entities that are 100% controlled by Advanced Oncotherapy plc.

The smallest and largest group into which the results of the company are consolidated is Advanced Oncotherapy plc. These financial statements are available to the public and may be obtained from the registered office at 143 Harley Street, Ground Floor, London, England, W1G 6BH.